Zacks Research Issues Negative Outlook for Revvity Earnings

Revvity Inc. (NYSE:RVTY) – Investment analysts at Zacks Research decreased their Q2 2026 earnings per share estimates for shares of Revvity in a research report issued on Tuesday, May 26th. Zacks Research analyst Team now forecasts that the company will post earnings of $1.26 per share for the quarter, down from their prior estimate of $1.31. The consensus estimate for Revvity’s current full-year earnings is $5.33 per share. Zacks Research also issued estimates for Revvity’s Q4 2026 earnings at $1.70 EPS, Q1 2027 earnings at $1.26 EPS, Q3 2027 earnings at $1.48 EPS, Q4 2027 earnings at $1.74 EPS, FY2027 earnings at $5.95 EPS, Q1 2028 earnings at $1.45 EPS and FY2028 earnings at $6.89 EPS.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Revvity had a return on equity of 8.00% and a net margin of 8.26%.The company had revenue of $711.12 million for the quarter, compared to analysts’ expectations of $704.07 million. During the same period in the previous year, the firm earned $1.01 EPS. The firm’s revenue was up 7.0% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS.

A number of other analysts also recently issued reports on the company. Evercore lifted their price objective on Revvity from $112.00 to $118.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 3rd. JPMorgan Chase & Co. reduced their price objective on Revvity from $96.00 to $90.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Wells Fargo & Company lifted their price objective on Revvity from $107.00 to $110.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 3rd. Barclays lifted their price objective on Revvity from $95.00 to $105.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. Finally, Weiss Ratings downgraded Revvity from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 13th. Four equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $107.73.

Revvity Stock Down 0.3%

NYSE RVTY opened at $96.69 on Wednesday. The company has a current ratio of 1.72, a quick ratio of 1.41 and a debt-to-equity ratio of 0.37. Revvity has a 12 month low of $81.22 and a 12 month high of $118.30. The stock’s 50 day moving average is $91.16 and its 200 day moving average is $97.06. The stock has a market cap of $10.79 billion, a PE ratio of 46.26, a P/E/G ratio of 2.09 and a beta of 1.05.

Hedge Funds Weigh In On Revvity

Several large investors have recently modified their holdings of RVTY. EdgePoint Investment Group Inc. grew its position in Revvity by 3.1% in the 1st quarter. EdgePoint Investment Group Inc. now owns 8,800,863 shares of the company’s stock valued at $771,044,000 after acquiring an additional 265,204 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Revvity by 5.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,606,637 shares of the company’s stock valued at $832,693,000 after acquiring an additional 434,570 shares during the last quarter. Janus Henderson Group PLC grew its position in Revvity by 2.3% in the 1st quarter. Janus Henderson Group PLC now owns 8,348,127 shares of the company’s stock valued at $731,386,000 after acquiring an additional 186,956 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Revvity by 11.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,917,953 shares of the company’s stock valued at $255,623,000 after acquiring an additional 305,837 shares during the last quarter. Finally, Morgan Stanley grew its position in Revvity by 29.6% in the 4th quarter. Morgan Stanley now owns 2,844,464 shares of the company’s stock valued at $275,202,000 after acquiring an additional 650,083 shares during the last quarter. Institutional investors own 86.65% of the company’s stock.

Revvity Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 7th. Stockholders of record on Friday, July 17th will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, July 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. Revvity’s payout ratio is currently 13.40%.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.